Literature DB >> 10371127

Lung infections in pediatric lung transplantation: experience in 49 cases.

D Metras1, L Viard, B Kreitmann, A Riberi, A Pannetier-Mille, O Garbi, J Y Marti, P Geigle.   

Abstract

OBJECTIVES: Pulmonary infections, and particularly cytomegalovirus (CMV) infections, are a major cause of morbidity after lung transplantation. We report here our results in 49 pediatric lung transplantations.
METHODS: Between may 1988 and 1997, we have done 49 lung transplantations in 42 children (en bloc double lung transplantation (DLT):10, HLTx:7, sequential bilateral sequential-lung transplantation (BSLT):31, single-lung transplantation (SLT): 1). In seven, it was a retransplantation. Among these, 34 were cystic fibrosis (CF) patients, all with multiresistant organisms (Pseudomonas aeruginosa, Burkholderia cepacia, Achromobacter xylososydans, Staphylococcus aureus). All patients were treated with multiantibiotic prophylaxy adapted to the preoperative cultures. Donor-recipient CMV matching was possible in only 31 cases. CMV prophylaxy and immunosuppression protocols have evolved with time, with a current protocol of IV Gancyclovir prophylaxy for 3 months and triple drug immunosuppression without post-operative rabbit anti-thymocyte globulin (RATG) induction. There was no perioperative mortality in the primary transplantations and three early deaths in the whole group (6.1%).
RESULTS: Only five patients had no pulmonary infection. The patients presented 3.2 infection episodes per year, 75% localized on the lungs, 41% during the first 3 months. Among the 13 deaths in the 1st year, 10 were directly related to infection, 60% due to CMV. After the 1st year, in all patients dying of pulmonary dysfunction or obliterative bronchiolitis (OB), bacterial infections were associated. There was no serious fungal infection. Actuarial survival at 3 months, 1, 3, 5 years were 85, 65.7, 47.5 and 28.5%, respectively. There was a significant difference in 3 year survival between patients receiving CMV negative organs (40%) and CMV positive organs (17%).
CONCLUSION: In our experience, as in other's, pulmonary infection risk is important in lung transplantation. Bacterial infections were mainly an aggravating factor of secondary pulmonary dysfunction or OB, and were not the primary cause of death. CMV infections have been very severe and lead us, despite the scarcity of donors, to avoid positive donors in negative recipients, this leads to disastrous mid-term results in our experience, despite prophylaxis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10371127     DOI: 10.1016/s1010-7940(99)00059-7

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  5 in total

1.  Safety and efficacy of prolonged cytomegalovirus prophylaxis with intravenous ganciclovir in pediatric and young adult lung transplant recipients.

Authors:  John F Spivey; Dana Singleton; Stuart Sweet; Gregory A Storch; Robert J Hayashi; Charles B Huddleston; Lara A Danziger-Isakov
Journal:  Pediatr Transplant       Date:  2007-05

2.  Fungal infections in pediatric lung transplant recipients: colonization and invasive disease.

Authors:  Michael Liu; Sarah Worley; George B Mallory; Sarah Arrigain; John Robertson; Marc G Schecter; Okan Elidemir; Lara A Danziger-Isakov
Journal:  J Heart Lung Transplant       Date:  2009-09-26       Impact factor: 10.247

3.  Increased mortality after pulmonary fungal infection within the first year after pediatric lung transplantation.

Authors:  Lara A Danziger-Isakov; Sarah Worley; Susana Arrigain; Paul Aurora; Manfred Ballmann; Debra Boyer; Carol Conrad; Irmgard Eichler; Okan Elidemir; Samuel Goldfarb; George B Mallory; Marian G Michaels; Peter Michelson; Peter J Mogayzel; Daiva Parakininkas; Melinda Solomon; Gary Visner; Stuart Sweet; Albert Faro
Journal:  J Heart Lung Transplant       Date:  2008-04-24       Impact factor: 10.247

4.  The risk, prevention, and outcome of cytomegalovirus after pediatric lung transplantation.

Authors:  Lara A Danziger-Isakov; Sarah Worley; Marian G Michaels; Susana Arrigain; Paul Aurora; Manfred Ballmann; Debra Boyer; Carol Conrad; Irmgard Eichler; Okan Elidemir; Samuel Goldfarb; George B Mallory; Peter J Mogayzel; Daiva Parakininkas; Melinda Solomon; Gary Visner; Stuart Sweet; Albert Faro
Journal:  Transplantation       Date:  2009-05-27       Impact factor: 4.939

5.  Cytomegalovirus viral load kinetics in patients with HIV/AIDS admitted to a medical intensive care unit: a case for pre-emptive therapy.

Authors:  Simnikiwe H Mayaphi; Marieke Brauer; Daniel M Morobadi; Ahmad H Mazanderani; Rendani T Mafuyeka; Steve A S Olorunju; Gregory R Tintinger; Anton Stoltz
Journal:  PLoS One       Date:  2014-04-03       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.